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ABSTRACT
Cystic fibrosis (CF) is caused by mutations in the CFTR gene. The spectrum of CFTR mutations varies be-
tween populations and depends on different factors, such as ethnic background and geographical location.
The extensive CFTR mutation screening of 129 patients with classical or atypical CF from the south-western
region of Sweden revealed the presence of 37 CFTR mutations, including 12 novel alleles. The overall muta-
tion detection rate in this study population was 92%, the highest among all tested regions in Sweden. Eight
mutations with a frequency above 1% (DF508, 394delTT, R117C, 3659delC, E60X, 1112delT, R764X, and
6211 1GR T) accounted for 78% of CF chromosomes and have been recommended for inclusion in the
CFTR mutation screening panel for molecular diagnosis of CF in this region. The multiple occurrence of spe-
cific CFTR alleles less common than the predominant DF508 mutation (394delTT, R117C, 3659delC) allowed
for genotype–phenotype comparisons and revealed consistent relationships between these mutations and dis-
ease severity.
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INTRODUCTION
CYSTIC FIBROSIS (CF) is one of the most common autosomalrecessive disorders in Caucasians (Welsch et al., 1994). The
estimated incidence of CF in Sweden is , 1:6000 of newborns,
with a carrier frequency of 1:50–60 (Selander, 1962). CF, in its
classic form, is characterized by chronic pulmonary disease, pan-
creatic insufficiency, and elevated concentrations of sweat elec-
trolytes. CF is caused by mutations in the cystic fibrosis trans-
membrane conductance regulator (CFTR) gene, which is located
on the long arm of chromosome 7. The gene encodes a trans-
membrane protein apically expressed in various epithelial cells
and functioning as a cAMP regulated chloride channel (Rom-
mens et al., 1989; Riordan et al., 1989). Since the initial char-
acterization of the CFTR gene and description of the most com-
mon mutation, DF508, over 1000 other mutations have been
reported worldwide (CF Genetic Analysis Consortium Web site;
November 2001: http//www.genet.sickkids.on.ca/cftr/).
CFTR mutations are associated with various molecular
mechanisms that may determine clinical severity of CF (Tsui,
1992; Welsh and Smith, 1993; Zielenski and Tsui, 1995). Gen-
erally, mutations producing CFTR variants with residual chlo-
ride channel function tend to be associated with milder CF pre-
sentations, although the particular phenotypic effect varies
between affected organs (Zielenski, 2000). The strongest cor-
relation between CFTR genotype and severity of cystic fibro-
sis symptoms has been observed for the pancreatic exocrine
function (Kristidis, 1992). In contrast, the pulmonary compo-
nent of the CF phenotype shows a rather poor correlation with
the CFTR genotype, probably due to the strong influence of en-
vironmental and secondary genetic factors (Zielenski, 2000).
The spectrum of CFTR mutations is population-specific and
varies between different populations and depends on ethnic
background and geographical location (The Cystic Fibrosis Ge-
netic Analysis Consortium, 1994). Analysis of the composition
and frequency of CFTR mutations in a particular population
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provides important information, both for the understanding of
mechanisms correlating genotype and phenotype, as well as for
the establishment of population-based molecular diagnostics.
Here we present the results of an extensive analysis of the
CFTR mutation spectrum in patients from the southwestern
Swedish CF Centre.
MATERIALS AND METHODS
Patients
All patients attending the Goteborg CF Centre (in Queen Sil-
via Children’s Hospital) during the period of 1995–1999 were
screened for mutations in the CFTR gene. Out of 129 patients
investigated, 125 (65 male and 60 female) presented with clas-
sical clinical manifestations in conjunction with an elevated
sweat test (Gibson and Cooke, 1959). Four patients with non-
diagnostic sweat test results were included because CF was sus-
pected due to pulmonary, gastrointestinal, and/or sinusitis
symptoms.
Clinical evaluation of the patients included age at diagnosis
and disease verification by X ray, spirometry, and regional lung
function tests with Tc99. Pseudomonas aeruginosa colonization
was defined as at least three consecutive sputum cultures dur-
ing the last 6 months and/or positive serum antibodies against
Pseudomonas antigens (Hollsing et al., 1987). Pancreatic sta-
tus was evaluated by determination of faecal chymotrypsin or
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TABLE 1. MUTATIONS IDENTIFIED IN 258 CHROMOSOMES IN THE CF POPULATION ATTENDING THE
SOUTH-WESTERN SWEDISH CF CENTRE
Location in the Frequency of
Mutation gene, exon Number of mutations mutation (%) Homozygotes Heterozygotes
DF508 10 161 62.4 56 49
394delTT 3 13 5.0 3 7
R117C 4 7 2.7 7
3659delC 19 5 1.9 5
E60X 3 4 1.6 4
1112delT 7 4 1.6 1 2
R764X 13 4 1.6 1 2
621 1 1G ® T 4 3 1.2 3
G551D 11 2 0.8 2
I506L 10 2 0.8 2
N1088D (R75Q) 17b 2 0.8 2
Q1238X 19 2 0.8 2
R117H (IVS8-5T) 4 2 0.8 2
V603F (IVS8-5T) 13 2 0.8 2
1716G ® A 10 2 0.8 2
R75Q 3 2 0.8 2
R533X 11 1 0.4 1
2329A ® G Promoter 1 0.4 1
297-3 C ® A 2 1 0.4 1
Y161D 4 1 0.4 1
994del9 Exon/intron 6b 1 0.4 1
1154insTC 7 1 0.4 1
W361R 7 1 0.4 1
T338I 7 1 0.4 1
1249-5A ® G Intron 7 1 0.4 1
1717-2A ® G Intron 10 1 0.4 1
R560T 11 1 0.4 1
E1401X 23 1 0.4 1
3126del4 17a 1 0.4 1
S945L 15 1 0.4 1
R668C 13 1 0.4 1
2622 1 2del6 Intron 13 1 0.4 1
R1162Q Exon 19 1 0.4 1
3849 1 10kbC ® T Intron 19 1 0.4 1
R74W Exon 3 1 0.4 1
2363C ® T Promoter 1 0.4 1
IVS8-5Ta Intron 8 1 0.4 1
Unidentified 20 7.8
Total 258 100 61 116
The new mutations are displayed in bold.
a Splicing site variation in the T-tract of intron 8.
Note: The patients carrying the 1112delT allele were related (siblings).
elastase activities, a fat tolerance test, and/or measurements of
pancreatic enzyme activity in duodenal juice after stimulation
with secretin and pancreozymin. Pancreatic sufficiency was de-
fined as a clinical history of normal growth, absence of gas-
trointestinal symptoms and fat malabsorption, and no need for
pancreatic enzyme replacement therapy.
Screening for CFTR mutations
Genomic DNA was obtained from peripheral blood of pa-
tients using the standard protocols. All patients were first ana-
lyzed for the most common CFTR mutation, DF508, and for
the second most common mutation in Scandinavia, 394delTT.
DF508 was detected by allele-specific PCR (Ballabio et al.,
1990) and 394delTT by heteroduplex analysis on polyacryl-
amide gels using the Pharmacia Phast System™. Patients neg-
ative for one or two of these mutations were then subjected to
mutation screening using polymerase chain reaction (PCR) and
multiplex heteroduplex (mHET) analysis on the Hydrolink gel
matrix (Zielenski et al., in press) and direct sequencing using
the Thermo Sequenase radiolabeled terminator cycle sequenc-
ing kit (USB). In addition, the thymidine tract (T-tract) in the
acceptor splice site in intron 8 was evaluated to detect the RNA
splice variant IVS8-5T (Mak et al., 1997).
RESULTS
Spectrum of CFTR mutations
The cumulative results of CFTR mutation screening in 129
CF patients (258 chromosomes) are presented in Table 1. DF08
deletion, the most common mutation in Caucasian populations,
was found in 62.4% (161/258) of the CF alleles. Of the re-
maining CF alleles, 77 (29.8%) carried 36 different CFTR mu-
tants/variants (Table 1). The second most common mutation,
the deletion 394delTT, characteristic for Nordic (Scandinavian)
population accounted for 5% of the CF alleles. Two other mu-
tations with frequencies exceeding 2% were R117C and
3659delC. Twenty mutations were carried on a single CF chro-
mosome. The margin of CF chromosomes with unidentified
mutations using this methodology was 7.8% (20/258) even
though the diagnosis of CF was clear (with the exception of 4
patients) from the clinical point of view, including pathologi-
cal sweat tests. The overall efficiency of CFTR mutation screen-
ing in this study population was 92.2%.
At the genotype level, 43% (56/129) of the patients were ho-
mozygous for the DF508 mutation and 38% (39/129) were com-
pound heterozygous for the DF508 allele and another mutation.
In addition, 5 patients were homozygous for other mutations;
three for 394delTT, and one each for 1112delT and R764X
(Table 1 and 2). Among the most common non-D508 alleles,
three (394del TT, R117C, and 3659delC) were detected in the
context of full CFTR genotypes in 22 CF patients (Table 2).
The availability of clinical data for the patients allowed for
genotype–phenotype correlations for the latter three alleles. The
394delTT mutation (n 5 13) was associated with a very severe
CF presentation, which includes high sweat chloride concen-
tration, pancreatic insufficiency (PI), moderate to severe lung
disease, and high rate of liver disease (, 40%). In contrast, pa-
tients (n 5 7) with the R117C allele (all paired with the DF508
deletion) tended to present with a mild form of CF [pancreatic
sufficiency (PS), good pulmonary status]. As expected, patients
with the 3659delC and DF508 mutations presented with severe
CF. One patient with the 3659delC allele and a mild mutation
on the second chromosome (I506L), presented with a mild form
of CF (Table 2).
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TABLE 2. CLINICAL PROFILES OF THE PATIENTS WITH MOST COMMON CFTR MUTATIONS (DF508 NOT INCLUDED)
Patient clinical data
Cl2
AD/yr (mmol/liter)
Mutation/ median Lung median
genotype n (range) PI/PS involvement MI (range) Other
394delTT 10 1.5 (0.1–12.2) 13/0a 10/10 1/10 109 (90–140)0
394delTT/DF508 7 1.5 (0.1–12.2) 7/0a 1/70 110 (90–140)0 4 with liver
disease of whom
1 died (B. cepacia
syndrome)
394delTT/394delTT 3 1.5 (0.8–4.2) 3/0a 0/3 102 (100–118)
R117C 7 5.5 (2.5–18) 0/7a 1/7 0/7 85 (71–100)
R117C/DF508 7 5.5 (2.5–18) 0/7a — 85 (71–100)
3659delC 5 0.8 (0.3–29) 4/1a 5/5 0/5 106 (80–116)0
3659delC/DF508 4 0.6 (0.3–8.0) 4/0a 0/4 107 (100–116) 2 double lung
transplanted (34,
28 years), of
whom 1 had
diabetes mellitus
3659delC/I506L 1 29 0/1* 0/1 80000000.
AD, Age at diagnosis in year; PS/PI, pancreatic status (sufficiency/insufficiency); Lung, lung disease; MI, meconium ileus;
Cl2, sweat chloride conc.; Other, other symptoms.
aThe second mutation (I507L) is mild; therefore, the patient is PS.
Besides the CFTR alleles previously reported by others, 12
novel mutations/variants were found in 17 patients. They rep-
resent different types of mutations (missense, nonsense,
frameshift, and RNA splice site), are located in various exon
and intron regions, and are associated with a spectrum of clin-
ical phenotypes (Table 3). Preliminary information on all new
mutations was submitted to the CF Genetic Analysis Consor-
tium (http://www.genet.sickkids.on.ca/cftr/).
Novel CFTR mutant variants
RNA splice mutations: 297-3CR A. This mutation was
caused by a transversion C to A in intron 2 at nucleotide posi-
tion 297-3 of the CFTR gene. The change is located in the ac-
ceptor splice site and may potentially affect the splicing of exon
3. The 297-3CR A allele was found in one patient carrying
the DF508 deletion on the other chromosome and presenting
with mild pulmonary disease and PI (Table 3).
262212del6. This is a 6-nucleotide (TAGGTA) non-
frameshift deletion in intron 13 starting at position 262212 and
affecting the 59 splice site. It was found in 1 patient with a se-
vere form of CF and the DF508 deletion on the other chromo-
some.
Frameshift and nonsense mutations: 994del9. Formally, it is
a frameshift mutation in exon 6b; however, since it also deletes
the first nucleotide (100111G) of the invariant 59 splice site in
intron 6b, it should be regarded as a splice site mutation. The
mutation is caused by the deletion of 9 nucleotides (TTAA-
GACAG) between positions 994 and 1002. It was found in a
young patient with meconium ileus, and PI but no symptoms
of lung disease. The patient carried the DF508 mutation on the
other chromosome.
1112delT. This frameshift mutation was found in exon 7 of
the CFTR gene, and it is caused by deletion of a single T at the
nucleotide position 1112. The allele was found in 3 patients,
including one homozygous for this allele. All patients (two of
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TABLE 3. CLINICAL DATA FOR THE CF PATIENTS CARRYING NEW MUTATIONS
Age PI Lung Sweat
(years) at or disease Cl
Mutations diagnosis PSb (severity) (mmol/liter) Additional symptoms
Frameshift
1112delT/1112delT 4 PI 111 110
1112delT/DF508 0.3 PI 111 112
1112delT/DF508 0.2a PI 111 110
3126del4/E60X 2 PI 11 130
994del9/DF508 0.08 PI 2 120 Meconium ileus
RNA splice
297-3C ® A/DF508 0.3 PI 1 120
2622 1 2del6/DF508 0.25 PI 111 100
Nonsense
E1401X/unknown 6 PS 2 52 Poor growth, fat malabsorption,
abnormal electrophysiological
response in the intestinal mucosal
biopsy
Missense
V603F, IVS8-5T/DF508 2 PI 1 101
N1088D, R75Q/DF508 4a PS 2 78
N1088D, R75Q/DF508 2 PS 2 75
Y161D/DF508 0.4 PI 1 83 Malabsorption
I506L/DF508 42.5 PS 111 103
I506L/3659delC 30 PS 111 80
R1162Q/unknown nvc PS 1 6 Frequent pneumonias
V603F, IVS8-5T/unknown nvc PS (1) 24 Sinusitis, severe recurrent
hypoglycemia, nasal polyps,
abdominal pain
Promoter?
2329A ® G/1716G ® A nvc PS (1) 50 Recurrent abdominal pain, nasal
polyps
2363C ® T/unknown nvc PS 2 43 Abdominal pain
aDiagnosis was obtained due to sick sibling.
bPI, pancreatic insufficiency; PS, pancreatic sufficiency.
cnv, not verified.
them siblings, also with the DF508 allele) presented with a se-
vere form of CF. All of these patients were related. The
1112delT allele in the siblings was inherited from their mother,
who is of Finnish origin.
3126del4. This frameshift mutation in exon 17a was caused
by deletion of 4 nucleotides (ATTA) between positions 3126
and 3129. The allele was found in 1 patient with the E60X mu-
tation on the other chromosome. The patient manifested with
an elevated sweat chloride concentration (100 mmol/liter), PI,
and moderate lung disease.
E1401X. This is a nonsense mutation in exon 23 caused by
a transversion G to T at nucleotide position 4333. In conse-
quence, it introduces a termination codon at the amino acid po-
sition 1401 of the CFTR polypeptide. Truncation of the termi-
nal portion of CFTR (up to , 98 amino acid residues)
destabilizes the complex-glycosylated form of the CFTR mol-
ecule (Haardt et al., 1999) without affecting its biosynthesis,
processing, and macroscopic channel function. The mutation
was found in a 6-year-old patient from Lebanon, presenting
with poor growth and fat malabsorption, but overall mild symp-
toms (sweat chloride 52 mmol/liter, no pulmonary symptoms,
and PS). He had a typical for CF electrophysiological response
in the intestinal mucosal biopsy (Hallberg et al., 2000). Because
the second mutation is unknown, the phenotypic status of the
E1401X cannot be established.
Besides changing the reading frame, these frameshift muta-
tions (994del9, 1112delT, and 3126del4) also introduce pre-
mature termination codons at or downstream of deletion points
(TAG at codon 307, TAA at codon 368, and TAA at codon 99,
respectively). In addition, the 994del9 mutation also affects a
splice site.
Missense mutations: Y161D. Located in the first cytoplas-
mic loop (CL1) in exon 4, this missense mutation was caused
by a transversion G to T at nucleotide position 613 and conse-
quently changes of tyrosine to aspartic acid at the amino acid
position 161. Mutations in the CL1 are known to alter a tran-
sition to open state of the CFTR chloride channel (Seibert et
al., 1997). The DF508 deletion was the second mutation in this
patient presenting with PI and malabsorption as the main symp-
toms, with a mild pulmonary disease. This child’s mother is
from Macedonia.
V603F. This missense mutation in exon 13 (R-domain) was
caused by a transversion of G to T at the position 1939 of the
CFTR gene and, in consequence, the change of valine to pheny-
lalanine at amino acid position 603. This allele was found in a
female patient with the DF508 as the second allele, and the
RNA splice site IVS8-5T variant co-segregating with the V603F
mutation. She has PI, pulmonary symptoms, and a sweat chlo-
ride of 101 mmol/liter. The mother is of East Indian origin. In-
terestingly, the mother’s sister carried the same mutation in con-
junction with the RNA splice site IVS8-5T variant, a second
mutation is as yet unidentified. She has normal sweat chloride
(28 mmol/liter), mild pulmonary disease, sinusitis, and severe,
recurrent hypoglycemia. Her CF diagnosis is, therefore, not ver-
ified.
I506L. A missense mutation within NBD1 (exon 10) was
caused by a transversion A to C at nucleotide position 1648
leading to the conservative amino acid change of isoleucine to
leucine at position 506. The mutation was found in 2 unrelated
patients; 1 with the I506L/DF508 genotype (sweat Cl2/103
mmol/liter, PS, and severe lung disease), and the other with the
I506L/3659delC genotype (sweat Cl2 80 mmol/liter, PS, and
severe lung disease). Both were diagnosed in adulthood at 42
and 30 years of age, respectively.
R1162Q. Located in the cytoplasmic segment of CFTR be-
tween TM12 and NBD2, this missense variant is caused by a
transversion G to A in exon 19 at nucleotide position 3617. It
leads to a change of arginine to glutamine at amino acid posi-
tion 1162. The female patient carrying this CFTR variant pre-
sented with frequent pneumonias, normal pancreatic function,
and sweat chloride levels (6 mmol/liter). The CF diagnosis has
not been verified in this patient. Although the second mutation
in this patient is unknown, the R1162Q allele is expected to be
very mild, because another mutation in this codon, R1162L was
previously classified as a normal variant (Fanen et al., 1992).
N1088D. This mutation was detected in the fourth cytoplas-
mic loop (CL4) of CFTR. It was caused by a transversion A to
G in exon 17b at nucleotide position 3394 and consequently,
replacement of asparagine by aspartic acid at amino acid posi-
tion 1088. The N1088D was found in two siblings (genotype
N1088D/DF508) with PS, and mild or no lung disease. There
was a third CFTR variant, R75Q, found in these patients and
associated with the N1088D allele.
In addition to the well-defined mutations listed above, 2 pa-
tients carried single nucleotide substitutions in the promoter re-
gion of the CFTR gene (positions 2363CR T or 2329AR
G). Without functional tests, however, it is not clear if these
changes are contributing to the phenotypes of these patients.
One female patient (with 2363CR T) presented has an atyp-
ical clinical presentation (recurrent abdominal pain, a border-
line sweat chloride of 43 mmol/liter, and normal pancreatic and
pulmonary functions). No other CFTR allele, except the intron
variant 1525-60 GR A was found in this patient. The patient
carrying the 2329AR G mutation also had recurrent abdom-
inal pain, a borderline sweat chloride of 50 mmol/liter, nasal
polyps, PS, and slight pulmonary involvement. The other mu-
tation in this patient was 1716GR A.
The summary of CFTR genotypes, consisting of the new
CFTR alleles and the corresponding clinical data is shown in
Table 3.
In our study population, there were 11 CF families with 2
affected siblings, and 1 with 3 affected children. All sibs had
the same CFTR genotypes, four homozygotes for DF508, and
the remainder was compound heterozygotes.
DISCUSSION
A total of 129 CF patients ascertained from CF clinics in the
southwestern region of Sweden were subjected to extensive mu-
tation screening of the entire CFTR gene. Effectively, the
screening protocol using the mHET included 1 kb of 59 un-
translated region (UTR) region, the 27 exons with flanking in-
trons, and some other specific regions (e.g., intron 19 for the
38491 10 kb CR T mutation). As a result, CFTR muta-
tions/variants were found in 92.2% (238/258) of the patients’
chromosomes. This overall detection rate is in agreement with
the method’s mutation screening capacity of 95%, as estimated
by the retrospective screening (Zielenski et al., in press). The
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screening led to the identification of 37 different CFTR alleles,
including 12 previously unknown mutations.
The allele frequency of the most common mutation DF508
was 62.4%, which is significantly lower than that previously
observed for the southern Swedish CF population (72%) (Korn-
falt et al., 1992) and the Danish CF population (88%) (Schwartz
et al., 1994). As expected, the 394delTT frameshift mutation
characteristic for Nordic populations (Schwartz et al., 1994)
was the second most common mutation in our study popula-
tion, at a frequency of 5.0%. This was lower than that reported
at the Lund center (9.3%). As with the southern region of Swe-
den (Lund), the second most common mutation (3659delC) in
the eastern part of the country (Uppsala 13.3%, Stockholm
10.5%), was much less represented in our patients (1.9%) and
it was surpassed by another mutation, R117C (2.7%) (Table 4).
Our study provides the most complete mutation screening
data of all the populations evaluated in different regions of Swe-
den, with the rate of detection of 92.2% (Table 4). A large num-
ber (33) of different CFTR mutations/variants, each with a low
frequency (20 of them occurred only once; Table 1), were de-
tected and characterized in 20.2% of CF chromosomes (Table
4) in this population. This finding probably reflects an increas-
ing ethnic complexity of the contemporary Swedish population.
Although the spectrum of mutations from other centers is not
completed with a significant number of CF chromosomes still
with unidentified mutations (, 15% of the total studied; Table
4), one may expect that these most likely represent rare muta-
tions, rather than more frequent ones already reported in other
centers. The differences in local mutation spectra are seen even
between nondistant regions. For example, in the southern part
of Sweden, which previously belonged to Denmark, only four
mutations accounted for 86% of the alleles, and in the south-
western part of Sweden, which is similar in terms of surface
area and population size, a much larger number, 19 mutations,
accounted for the same percentage (Tables 1 and 4).
The relatively high frequency of the 394delTT (3 homozy-
gotes) R117C and 3659delC alleles made it possible to draw
genotype–phenotype correlations for patients carrying these
mutations (Table 2). Patients carrying the 394delTT mutation
(either homozygous for this allele, or compound heterozygotes
with the DF508) tend to present with the severe phenotype, with
symptoms including PI at an early age and lung disease with
chronic or intermittent Pseudomonas aeruginosa colonization.
One patient died at the age of 18 with the “Burkholderia cepa-
cia syndrome.” In addition, these patients had a high incidence
of biochemical liver disease, the frequency of which was not
significantly different from that in homozygotes for DF508
(36%). This is in agreement with an earlier prospective study
of liver disease in Sweden where no relation could be found
between genotype and liver disease (Lindblad et al., 1999).
The group of patients with the combination of mutations
3659delC and DF508 had a similar phenotype to that in patients
with 394delTT with early disease diagnosis, PI, and severe lung
disease. One patient with I506L and 3659delC was diagnosed
at a later age and presented with PS, but severe lung disease.
In the group carrying the mild R117C allele all patients were
PS and diagnosed at older ages. Characteristically, all but one
of these patients has normal lung function and none of them
were chronically colonized with P. aeruginosa. Only 1 patient
has slight bronchiectasis with intermittent growth of Staphylo-
coccus aureus.
Beside the CFTR mutations reported before, 12 novel CFTR
alleles have been found in this study population (Tables 1 and
3). The clinical data associated with these mutations are listed
in Table 3. Five of these mutations belong to the class I muta-
tions that severely affect the synthesis and/or structure of CFTR
protein and are therefore associated with more severe CF phe-
notypes, provided that the other allele is also severe (Tsui, 1992;
Zielenski and Tsui, 1995). Interestingly, one of these mutations
(E1401X) is associated with a very mild CF presentation (age
at diagnosis, 6 years; borderline sweat chloride levels of 52
mmol/liter, PS, and no lung symptoms). Although the second
mutation in this patient has not yet been identified, there is a
possibility that the CFTR carboxy-terminal truncation caused
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TABLE 4. REGIONAL DISTRIBUTION OF CFTR ALLELE FREQUENCY IN SWEDEN
CFTR alleles
All
identified
Center n % n % n % n % n % n % Nm (%)
Uppsalaa 60 6.6 35 58.3 4 6.7 8 13.3 ndc
Stockholma 354 38.5 238 67.2 29 8.2 37 10.5 ndc 15 2.3 8 84.7
Lunda 248 26.9 179 72.1 23 9.3 7 2.8 6d 2.3
Goteborgb 258 28 161 62.4 13 5.0 5 1.9 7d 2.7 52 20.2 33 92.2
Sweden 920 100.0 613 66.6 69 7.5 57 6.2 13d 1.4 67 7.3 89.0
total
aThe data for Uppsala, Stockholm, and Lund were presented according to the published report (Schaedel et al., 1999).
bThis study.
cnd, No data.
dR117C or R117H.
eThis section contains data corresponding to other less common mutations. n and % refer to number and proportion of CF
chromosomes carrying the other CFTR alleles. The “Nm” column represents the number of different CFTR mutant alleles iden-
tified among CF chromosomes not carrying most common mutations (DF508, 394delTT, 3659delC, and R117C). Results from
other centers are cumulative.
Patient 
chromosomes DF508 394delTT 3659delC R117C Othere
by the nonsense mutation may produce a relatively unstable but
fully functional CFTR channel that may partially account for
the milder presentation (Haardt et al., 1999). Frameshift and
nonsense mutations belonging to this category may be put in a
new class (VI) of mutations based on their distinct molecular
mechanism leading to protein instability (Haardt et al., 1999;
Zielenski, 2000).
The remaining mutations are mainly of the missense type
and probably represent different classes. Two of them (V603F
and Y161D) are associated with PI, moderate-to-severe lung
disease, and elevated sweat chloride levels. The remaining mis-
sense variants (I506L, N1088D, and R1162Q) can be classified
as mild alleles because they are associated with a milder CF
phenotype in genotypes with a severe second allele. These mis-
sense mutations are probably of the class IV or V types, which
are associated with a residual CFTR function. Besides these
missense variants, there is also splice mutation in the 23 posi-
tion of the acceptor splice site in intron 2 (297-3 CR A). The
nucleotide alterations in this position are less restrictive for the
splice selection and recognition process and are expected to pro-
duce some amount of correctly spliced mRNA transcript (class
V). Indeed, the mutation was associated with a milder CF pre-
sentation (Table 3). Finally, there were two alleles (2363CR
T and 2329AR G) identified in the 59 UTR (promoter) re-
gion. The former variant was found in a patient with border-
line sweat Cl2 (43 mmol/liter), recurrent abdominal pain, but
no pancreatic or lung disease. Without a functional study it is
impossible to verify the disease-causing status of this mutation;
however a second mutant allele was not found in this patient.
Near-complete screening of a local CF population provides
important information for establishing the most optimal strate-
gies for routine screening of CF patients in this population. Our
results indicate that an adjustment should be made to the panel
of most common mutations used in the screening of the south-
western Swedish CF population: the addition of the R117C mu-
tation (2.7% of CF chromosomes; Table 1). This mutation is
known to be associated with a variety of clinical presentations,
extending from congenital bilateral absence of the vas deferens
(CBAVD) to mild CF (Massie et al., 1999; Barolozzi et al.,
2000). The phenotypic effect of this mutation, like that of the
more common R117H allele, may depend on the length of the
T-tract variant in intron 8 (Massie et al., 1999). Screening for
this mutation will be especially relevant for the patients pre-
senting with the atypical or milder form of CF and will require
the T-tract evaluation.
As more clinical presentations resembling CF are being
brought to medical attention, it has become a challenge to make
a firm diagnosis of CF based on atypical clinical findings and
negative or partially negative results of a genetic analysis of the
CFTR gene. This also raises questions as to where to draw the
line between CF and CF-like clinical phenotypes. One exam-
ple from our study population is a patient with an atypical CF
presentation (recurrent abdominal pain; borderline sweat chlo-
ride; normal pancreatic and pulmonary function). The CFTR
mutation screening revealed the presence of a potential pro-
moter mutation 2363 CR T in the 59UTR region but not other
well-defined CFTR allele. If we assume that the 2363CR T
variant is indeed affecting CFTR function, was a second muta-
tion required to produce the clinical manifestations observed in
this patient? Interestingly, the overall CFTR mutation detection
rate (even when using efficient mutation screening methods) in
patients presenting with very mild or atypical CF tends to be
much lower (50–60%) than that observed in patients with clas-
sic CF (90–100%) (Zielenski, Walker, and Tsui, unpublished
data). This and other observations are consistent with the idea
that the carrier state under certain—yet undefined—conditions
may lead to an atypical CF phenotype (Bronsveld et al., 1999).
One possible explanation is an impact of secondary genetic fac-
tors that may, through as yet unknown molecular mechanisms,
contribute to expression of CF-like symptoms in carriers of
CFTR mutations (Zielenski et al., 2000).
Another important issue is making the diagnosis of CF in
such atypical cases. Many of them would not be diagnosed as
CF under currently recommended CF diagnosis criteria (Rosen-
stein and Cutting, 1998). This poses serious problems for physi-
cians and genetic counselors when trying to interpret the clin-
ical and genetic data available for a particular patient to make
a definitive CF diagnosis.
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